{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.2","value":"2.4"},{"groupId":"OG001","spread":"3.0","value":"7.2"},{"groupId":"OG002","spread":"8.3","value":"21.2"},{"groupId":"OG003","spread":"13.3","value":"54.8"},{"groupId":"OG004","spread":"17.4","value":"45.2"},{"groupId":"OG005","spread":"38.6","value":"81.2"},{"groupId":"OG006","spread":"17.3","value":"59.6"},{"groupId":"OG007","spread":"46.0","value":"110.5"},{"groupId":"OG008","spread":"41.5","value":"87.3"},{"groupId":"OG009","spread":"22.7","value":"57.0"},{"groupId":"OG010","spread":"34.1","value":"70.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"11"}],"units":"Participants"}],"description":"The lowest (trough) concentration of dalotuzumab prior to the next dose of dalotuzumab was measured.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received dalotuzumab 1.25 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG000","title":"Dalotuzumab 1.25 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 2.5 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG001","title":"Dalotuzumab 2.5 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 5 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG002","title":"Dalotuzumab 5 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 10 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG003","title":"Dalotuzumab 10 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 10 mg/kg (20 mg/mL) IV infusion Q1W.","id":"OG004","title":"Dalotuzumab 10 mg/kg Q1W (20 mg/mL)"},{"description":"Participants received dalotuzumab 15 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG005","title":"Dalotuzumab 15 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 15 mg/kg (20 mg/ mL) IV infusion Q1W.","id":"OG006","title":"Dalotuzumab 15 mg/kg Q1W (20 mg/mL)"},{"description":"Participants received dalotuzumab 20 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG007","title":"Dalotuzumab 20 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 20.0 mg/kg (20 mg/mL) IV infusion Q1W.","id":"OG008","title":"Dalotuzumab 20 mg/kg Q1W (20 mg/mL)"},{"description":"Participants received dalotuzumab 20 mg/kg (20 mg/mL) IV infusion Q2W.","id":"OG009","title":"Dalotuzumab 20 mg/kg Q2W (20 mg/mL)"},{"description":"Participants received dalotuzumab 30 mg/kg (20 mg/mL) IV infusion Q3W.","id":"OG010","title":"Dalotuzumab 30 mg/kg Q3W (20 mg/mL)"}],"paramType":"MEAN","populationDescription":"The population consisted of all evaluable participants who received \\>90% of intended drug volume and had mean trough serum concentration pharmacokinetic measurements at Baseline and at least once during treatment.","reportingStatus":"POSTED","timeFrame":"Pre-dose immediately prior to second infusion: 168 hours for Q1W, 336 hours for Q2W and 504 hours for Q3W dosing","title":"Mean Trough Serum Concentration (Ctrough) of Dalotuzumab","type":"PRIMARY","unitOfMeasure":"ug/mL"}